Introduction: Canagliflozin, a sodium glucose
observed in previous studies, with increased incidence of AEs related to the mechanism of SGLT2 inhibition (e.g., genital mycotic infections, urinary tract infections, and osmotic diuresis-related AEs) and a low risk of hypoglycemia.
Conclusion:
More patients treated with canagliflozin experienced reductions in both HbA1c and body weight compared with glimepiride for up to 104 weeks. Canagliflozin was generally well tolerated in patients with T2DM when used in combination with metformin.
INTRODUCTION
Current guidelines for the management of type 2 diabetes mellitus (T2DM) routinely recommend metformin as first-line therapy in those who are able to tolerate this agent [1] . However, there are numerous options for second-line therapies for use in combination with metformin in individuals unlikely to achieve their target HbA1c levels with metformin alone. Among these, sulfonylureas are a well-established drug class, but they are typically associated with weight gain and hypoglycemia [1, 2] . Many patients with T2DM are overweight or obese, and further increases in body weight may be detrimental to their well-being, particularly increasing the risk of cardiovascular disease and microvascular disease [3] .
Sodium glucose co-transporter 2 (SGLT2) inhibitors are another therapeutic class recommended in current guidelines as an option for combination therapy with metformin and are associated with weight loss and a low risk of hypoglycemia [1] .
Canagliflozin is an SGLT2 inhibitor approved for the treatment of adults with T2DM [4] . Canagliflozin reduces plasma glucose levels by lowering the renal threshold for glucose, thereby increasing urinary glucose excretion [5, 6] . In a head-to-head study of canagliflozin versus the sulfonylurea glimepiride as add-on to metformin in patients with T2DM, canagliflozin has demonstrated sustained improvements in glycemic control, together with sustained reductions in body weight, over 104 weeks [7, 8] .
In addition to measuring HbA1c in patients with T2DM, there is increasing recognition of the value of using composite endpoints to evaluate T2DM treatments [9] . Since glycemic control and weight loss are beneficial for most patients with T2DM, this post hoc analysis evaluated the effect of canagliflozin versus glimepiride on reducing both HbA1c and body weight in patients with T2DM inadequately controlled with metformin for up to 104 weeks of treatment.
METHODS

Study Design
This post hoc analysis was based on data from a 104-week, randomized, double-blind, consecutive days during the study.
Endpoints
Change in HbA1c and percent change in body weight from baseline were pre-specified study endpoints. Using individual patient data, the proportion of patients who achieved a decrease from baseline in both HbA1c (%) and body weight (kg) was assessed at Weeks 52 and 104.
Safety was assessed based on adverse event (AE) reports. Documented hypoglycemia episodes included biochemically documented episodes (concurrent fingerstick glucose or plasma glucose B3.9 mmol/L with or without symptoms) and severe episodes (i.e., requiring the assistance of another individual or resulting in seizure or loss of consciousness).
Statistical Analyses
Analyses were performed using the modified intent-to-treat (mITT) population, which consisted of all randomized patients who received C1 dose of study drug. The last observation carried forward (LOCF) approach was used to impute missing data. Efficacy 
RESULTS
Patient Disposition and Baseline Characteristics
A total of 1450 subjects comprised the mITT and safety analysis sets; 71.0%, 66.6%, and 65.1% completed the 104-week, double-blind treatment period with canagliflozin 100 and 300 mg and glimepiride, respectively [8] . 
Safety
Details of the safety of canagliflozin 100 and 300 mg versus glimepiride over 104 weeks have been previously reported [8] . Briefly, the overall incidence of AEs was 73.3%, 77.9%, and 78.4%
with canagliflozin 100 and 300 mg and glimepiride, respectively; the incidence of AEs leading to discontinuation was 6.2%, 9.5%, and 7.3%, respectively, and the incidence of serious AEs was 9.7%, 9.7%, and 14.3%, respectively.
Incidences of genital mycotic infections in men (9.5% and 9.1% vs 1.9%) and women (13.9% and 15.6% vs 2.7%), urinary tract infections Mean ± SD HbA1c (%) 7.8 ± 0.8 7.8 ± 0.8 7.8 ± 0.8
Mean ± SD duration of T2DM (years) 6.6 ± 5.0 6.5 ± 5.5 6.7 ± 5.5
CANA canagliflozin, GLIM glimepiride, SD standard deviation, T2DM type 2 diabetes mellitus a Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, and other A previous study suggested that *40% of patients with T2DM who are receiving metformin monotherapy and add a sulfonylurea to their treatment regimen will gain weight in the year following intensification of therapy [3] . Additionally, with every increase in BMI category (from normal to severely obese), the rate of hospitalizations for cardiovascular disease, stroke, amputation, blindness, and end-stage renal disease rose [3] . Thus, in addition to improvements in glycemic control, the reductions in body weight provided by canagliflozin make it a promising treatment option for patients with T2DM who are overweight or obese. The benefits of weight loss on other diabetes-related outcomes with canagliflozin have been demonstrated in an analysis of pooled data from 4 randomized, double-blind, placebo-controlled trials in which *15% of HbA1c lowering and *40% of systolic blood pressure lowering was associated with weight loss; thus, each 1% reduction in body weight was associated with a 0.045% decrease in HbA1c and a 0.62 mmHg reduction in systolic blood pressure [16] . Indeed, a reduction of 5-10% in body weight in patients with T2DM is associated with beneficial effects on glycemia, blood pressure, high-density lipoprotein cholesterol (HDL-C), and triglycerides [17] . However, it is unknown whether these benefits will translate to improvement in long-term clinical outcomes, including cardiovascular disease. Patients with T2DM with pre-existing cardiovascular disease who had reductions in HbA1c, body weight, and blood pressure with the SGLT2 inhibitor empagliflozin were shown to have decreased risk of cardiovascular events and mortality [18] .
The ongoing CANagliflozin cardioVascular Assessment Study (CANVAS; ClinicalTrials.gov Identifier: NCT01032629) and CANVAS-R (renal endpoints; NCT01989754) trials will evaluate the long-term efficacy and safety, including cardiovascular outcomes, of canagliflozin in patients with T2DM and a history or high risk of cardiovascular disease [19] . is a full-time employee of Janssen Scientific Affairs, LLC. 
